Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

News provided by

Mar 18, 2013, 08:25 ET

NEW YORK, March 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

http://www.reportlinker.com/p0453472/Methicillin-resistant-Staphylococcus-aureus-MRSA-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

Scope

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Introduction 82.1 Overview 82.1.1 Hospital-acquired MRSA (HA-MRSA) 82.1.2 Community-acquired MRSA (CA-MRSA) 82.1.3 Historical Aspect of MRSA Infection 92.1.4 Genetic Variance between CA-MRSA and HA-MRSA 92.2 Epidemiology 112.2.1 Historic Epidemiology (2006-2011) 112.2.2 Forecasted Epidemiology (2011-2019) 112.3 Prognosis 132.4 Etiology 132.5 Symptoms 142.6 Diagnosis 152.6.1 Bacterial Culture 152.6.2 ChromAgar Technique 152.6.3 Latex Agglutination Test 152.6.4 Molecular Detection 152.7 Pathophysiology 162.7.1 Molecular Pathogenesis of MRSA 162.7.2 Mechanism of Resistance 182.7.3 Transmission of MRSA 182.8 Treatment and Management Pattern 192.9 Referral Pathway 222.10 GlobalData Pipeline Report Guidance 233 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Market Characterization 243.1 MRSA Therapeutics Market Size (2006-2011) - Global 243.2 MRSA Therapeutics Market Forecast (2011-2019) - Global 263.3 MRSA Therapeutics Market Size (2006-2011) - The US 283.4 MRSA Therapeutics Market Forecast (2011-2019) - The US 293.5 MRSA Therapeutics Market Size (2006-2011) - France 303.6 MRSA Therapeutics Market Forecast (2011-2019) - France 313.7 MRSA Therapeutics Market Size (2006-2011) - Germany 323.8 MRSA Therapeutics Market Forecast (2011-2019) - Germany 333.9 MRSA Therapeutics Market Size (2006-2011) - Italy 353.10 MRSA Therapeutics Market Forecast (2011-2019) - Italy 363.11 MRSA Therapeutics Market Size (2006-2011) - Spain 383.12 MRSA Therapeutics Market Forecast (2011-2019) - Spain 393.13 MRSA Therapeutics Market Size (2006-2011) - The UK 413.14 MRSA Therapeutics Market Forecast (2011-2019) - The UK 423.15 MRSA Therapeutics Market Size (2006-2011) - Japan 443.16 MRSA Therapeutics Market Forecast (2011-2019) - Japan 453.17 Drivers and Barriers for the MRSA Therapeutics Market 463.17.1 Drivers for the MRSA Therapeutics Market 463.17.2 Barriers for the MRSA Therapeutics Market 463.18 Opportunity and Unmet Need 483.19 Key Takeaway 514 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - - Competitive Assessment 524.1 Overview 524.2 Strategic Competitor Assessment 524.3 Product Profile for the Major Marketed Products in the MRSA Therapeutics Market 544.3.1 Zyvox (linezolid) 544.3.2 Cubicin (daptomycin) 554.3.3 Tygacil (tigecycline) 574.3.4 Vibativ (telavancin) 584.3.5 Teflaro (ceftaroline) 594.3.6 Vancocin (vancomycin) 614.4 Key Takeaway 635 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment 645.1 Overview 645.2 Strategic Pipeline Assessment 645.3 MRSA Therapeutics- Pipeline Analysis by Phase of Development 655.3.1 MRSA Therapeutics- Phase III Pipeline 655.3.2 MRSA Therapeutics- Phase II Pipeline 665.3.3 MRSA Therapeutics- Phase I Pipeline 675.3.4 MRSA Therapeutics- Pre-Clinical Pipeline 685.3.5 MRSA Therapeutics- Discovery Pipeline 695.3.6 MRSA Therapeutics- Unknown Phase Pipeline 705.4 MRSA Therapeutics- Pipeline by Mechanism of Action 715.5 Technology Trends Analytical Framework 735.6 Most Promising Drug Profiles 745.6.1 Torezolid phosphate (TR-701, Tedizolid) 745.6.2 Ceftobiprole Medocaril 755.6.3 Dalbavancin 765.6.4 Oritavancin 775.7 Key Takeaway 776 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics -Clinical Trials Mapping 786.1 Clinical Trials by Region and Country 786.2 Clinical Trials by Phase of Clinical Development 796.3 Clinical Trials by Trial Status 806.4 Clinical Trials by Sponsors 816.5 Top Companies Participating in MRSA Clinical Trials 837 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Strategic Assessment 847.1 Key Events Impacting the Future Market 847.2 Future Market Competition Scenario 858 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Future Players 878.1 Introduction 878.2 Company Profiles 888.2.1 Basilea Pharmaceutica Ltd. 888.2.2 Durata Therapeutics, Inc. 898.2.3 The Medicines Company 898.2.4 Trius Therapeutics, Inc. 908.2.5 AstraZeneca PLC 918.2.6 GlaxoSmithKline plc 938.2.7 Rib-X Pharmaceuticals, Inc. 948.2.8 Wockhardt Limited 958.3 Details of Other Companies in the Pipeline 978.4 Key Takeaway 1009 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Licensing and Partnership Deals 10110 KOL Insights 10411 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Appendix 10511.1 Definitions 10511.2 Abbreviations 10511.3 Bibliography 10711.4 Research Methodology 10811.4.1 Coverage 10811.4.2 Secondary Research 10811.4.3 Forecasting 10911.4.4 Primary Research 11111.4.5 Expert Panel Validation 11211.5 Contact Us 11211.6 Disclaimer 112

List of Tables

Table 1: Historic Epidemiology, Prevalent Population, 2006-2011 11Table 2: Forecasted Epidemiology, Prevalent Population, 2011-2019 11Table 3: Recommendations for the Treatment of Methicillin-Resistant Staphylococcus aureus 21Table 4: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Global, Revenue ($m), 2006-2011 25Table 5: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Global, Forecast ($m), 2011-2019 27Table 6: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The US, Revenue ($m), 2006-2011 28Table 7: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The US, Forecast ($m), 2011-2019 29Table 8: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, France, Revenue ($m), 2006-2011 30Table 9: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, France, Forecast ($m), 2011-2019 31Table 10: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Germany, Revenue ($m), 2006-2011 32Table 11: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Germany, Forecast ($m), 2011-2019 34Table 12: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Italy, Revenue ($m), 2006-2011 35Table 13: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Italy, Forecast ($m), 2011-2019 37Table 14: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Spain, Revenue ($m), 2006-2011 38Table 15: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Spain, Forecast ($m), 2011-2019 40Table 16: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The UK, Revenue ($m), 2006-2011 41Table 17: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The UK, Forecast ($m), 2011-2019 43Table 18: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Japan, Revenue ($m), 2006-2011 44Table 19: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Japan, Forecast ($m), 2011-2019 45Table 20: Methicillin - Resistant Staphylococcus aureus Therapeutics - Drug Information 62Table 21: Methicillin - Resistant Staphylococcus aureus Therapeutics - Phase III Pipeline, 2012 65Table 22: Methicillin - Resistant Staphylococcus aureus Therapeutics - Phase II Pipeline, 2012 66Table 23: Methicillin - Resistant Staphylococcus aureus Therapeutics - Phase I Pipeline, 2012 67Table 24: Methicillin - Resistant Staphylococcus aureus Therapeutics - Pre-Clinical Pipeline, 2012 68Table 25: Methicillin - Resistant Staphylococcus aureus Therapeutics - Discovery Pipeline, 2012 69Table 26: Methicillin - Resistant Staphylococcus aureus Therapeutics - Unknown Phase Pipeline, 2012 70Table 27: Development Status of Ceftobiprole 76Table 28: Development status of Dalbavancin 77Table 29: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Clinical Trials, 2012 78Table 30: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Clinical Trials by Phase, 2012 79Table 31: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Clinical Trials by Status of Development, 2012 80Table 32: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Overall Sponsors, 2012 81Table 33: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Prominent Sponsors, 2012 82Table 34: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Top Ten Companies by Phase, 2012 83Table 35: Basilea - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 88Table 36: Durata Therapeutics - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 89Table 37: The Medicines Company - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 90Table 38: Trius Therapeutics - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 91Table 39: AstraZeneca - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 92Table 40: GlaxoSmithKline Pipeline Products 2012 94Table 41: Rib-X Pharmaceuticals - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 95Table 42: Wockhardt - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 96Table 43: Description of Other Companies in the Pipeline, 2012 97Table 44: Methicillin - Resistant Staphylococcus aureus Therapeutics, Licensing and Partnership Deals, 2012 101

List of Figures

Figure 1: Classification of Methicillin-Resistant Staphylococcus aureus Infection 9Figure 2: Methicillin-Resistant Staphylococcus aureus Therapeutics - Comparison of HA-MRSA and CA-MRSA Infections 10Figure 3: Methicillin-Resistant Staphylococcus aureus Therapeutics - Treatment Flow Analysis 12Figure 4: KOL Insights, Methicillin - Resistant Staphylococcus aureus in the US 12Figure 5: Methicillin-Resistant Staphylococcus aureus Therapeutics - Skin Infection (abscess) 14Figure 6: Methicillin-Resistant Staphylococcus aureus Therapeutics - Comparison of Method of Detection 16Figure 7: Virulence factors of S. aureus 17Figure 8: Clinical Spectrum of Methicillin - Resistant Staphylococcus aureus Cases 17Figure 9: Susceptibility of Antibiotics for Methicillin - Resistant Staphylococcus aureus 18Figure 10: Methicillin-Resistant Staphylococcus aureus Therapeutics - Treatment Algorithm 20Figure 11: Methicillin-Resistant Staphylococcus aureus Therapeutics - Management of Infection 21Figure 12: Methicillin - Resistant Staphylococcus aureus Therapeutics - Referral Pathway 22Figure 13: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Global, Revenue ($m), 2006-2011 25Figure 14: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Global, Forecast ($m), 2011-2019 27Figure 15: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The US, Revenue ($m), 2006-2011 28Figure 16: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The US, Forecast ($m), 2011-2019 29Figure 17: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, France, Revenue ($m), 2006-2011 30Figure 18: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, France, Forecast ($m), 2011-2019 31Figure 19: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Germany , Revenue ($m), 2006-2011 32Figure 20: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Germany, Forecast ($m), 2011-2019 33Figure 21: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Italy, Revenue ($m), 2006-2011 35Figure 22: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Italy, Forecast ($m), 2011-2019 36Figure 23: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Spain, Revenue ($m), 2006-2011 38Figure 24: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Spain, Forecast ($m), 2011-2019 39Figure 25: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The UK, Revenue ($m), 2006-2011 41Figure 26: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The UK, Forecast ($m), 2011-2019 42Figure 27: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Japan, Revenue ($m), 2006-2011 44Figure 28: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Japan, Forecast ($m), 2011-2019 45Figure 29: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Drivers and Barriers, 2012 47Figure 30: Comparison of First and Second Generation Oxazolidinone 48Figure 31: Comparison of Advantages and Disadvantages of Torezolid With Vancomycin and Linezolid 49Figure 32: Opportunity and Unmet Need in the Methicillin - Resistant Staphylococcus aureus Therapeutics Market, 2012 50Figure 33: KOL Insights, Unmet Medical Needs 51Figure 34: Strategic Competitor Assessment of the Marketed Products in Methicillin - Resistant Staphylococcus aureus Therapeutics, 2012 52Figure 35: KOL Insights, Limitation of Available Treatment Options 53Figure 36: Molecular Structure of Linezolid 54Figure 37: Molecular Structure of Daptomycin 55Figure 38: Molecular Structure of Tigecycline 57Figure 39: Molecular Structure of Telavancin Hydrochloride 58Figure 40: Molecular Structure of Ceftaroline 60Figure 41: Molecular Structure of Vancomycin Hydrochloride 61Figure 42: Methicillin - Resistant Staphylococcus aureus Therapeutics- Clinical Pipeline by Phase of Development (%), 2012 70Figure 43: Methicillin - Resistant Staphylococcus aureus Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2012 71Figure 44: Methicillin - Resistant Staphylococcus aureus Therapeutics, Clinical Pipeline by Drug Class (%), 2012 72Figure 45: Technology Trends Analytics Framework, 2012 73Figure 46: Technology Trends Analytics Framework - Description, 2012 74Figure 47: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Clinical Trials by Country, 2012 78Figure 48: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Clinical Trials by Phase (%), 2012 79Figure 49: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Clinical Trials by Status of Development (%), 2012 80Figure 50: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Overall Sponsors (%), 2012 81Figure 51: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Prominent Sponsors (%), 2012 82Figure 52: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Top Companies by Phase, 2012 83Figure 53: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, An Impact Analysis, 2012 84Figure 54: Implications for Future Market Competition in the Methicillin - Resistant Staphylococcus aureus Therapeutics Market, 2012 85Figure 55: Methicillin - Resistant Staphylococcus aureus Therapeutics, Clinical Pipeline by Company, 2012 87Figure 56: KOL Insights, Methicillin - Resistant Staphylococcus aureus Infection, Major Market 104Figure 57: GlobalData Market Forecasting Model 111